Dataset from A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure With Reduced Ejection Fraction (HFrEF)

Objective of the study is to find the optimal dose of the once daily oral soluble guanylate
cyclase stimulator (sGC) BAY1021189 for Phase III that can be given in addition to standard
therapy for heart failure with reduced ejection fraction (HFrEF).